Peripherial T Cell Lymphoma,Not Otherwise Specified: Clinical Trials

1 trial for Peripherial T Cell Lymphoma,Not Otherwise Specified, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 unknown. 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 41Unknown 1

Follow Peripherial T Cell Lymphoma,Not Otherwise Specified: new trials by email Literature Review of Peripherial T Cell Lymphoma,Not Otherwise Specified trials Research Report on Peripherial T Cell Lymphoma,Not Otherwise Specified

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Cyclophosphamide 750mg/m2, Vincristine 1.4mg/m2, Doxorubicin 50mg/m2 - ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified
Phase 4UnknownRuijin Hospital2002012-09-012017-11-14

Narrower conditions

Enteropathy-Associated T-Cell Lymphoma (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Subcutaneous panniculitis-like T-cell lymphoma (1)

Broader conditions

Hemic and Lymphatic Diseases (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphadenopathy (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoma, T-Cell (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)

Interventions

Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  Etoposide (1)  ·  Ifosfamide (1)  ·  Methotrexate (1)  ·  Prednisone (1)  ·  Vincristine (1)  ·  etoposide phosphate (1)  ·  pirarubicin (1)  ·  prednylidene (1)

Sponsors

Ruijin Hospital (1)

Countries

China (1)